Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD4818 · 2 trials · 2 indications
Number of patients who had an Adverse Event
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | AZD4818 |
| 2 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| AZD4818 | DRUG | Dry Powder, inhalation, b.i.d., 4 weeks |
| Placebo | DRUG | - |
Inclusion Criteria: * Clinical diagnosis of COPD, with symptoms for more than 1 year * Current or ex-smokers with a smoking history of at least 10 pack-years (1 pack-year=20 cigarettes/day for 1 year) * Lung function (FEV1) 40 to 80% of the predicted normal value after using a short acting bronchod...
AZD4818 is an investigational small molecule being studied for the treatment of moderate to severe chronic obstructive pulmonary disease (COPD). It is administered via inhalation and has been evaluated in clinical trials for its tolerability, safety, and efficacy in patients with COPD.
AZD4818 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The drug is currently in clinical development for respiratory conditions, specifically COPD.
AZD4818 has completed Phase 2 clinical trials for COPD. It is an investigational drug and has not been approved by regulatory authorities. The development program includes both Phase 1 and Phase 2 studies that have been completed.
AZD4818 has been studied in two completed clinical trials. NCT00629239 was a Phase 2 study in patients with moderate to severe COPD, enrolling 65 participants across Denmark, Finland, Netherlands, Norway, and Sweden. NCT00687232 was a Phase 1 study in healthy Japanese male volunteers, enrolling 30 participants in Japan.
AZD4818 is a small molecule administered by inhalation for the treatment of COPD. The specific molecular target of AZD4818 has not been disclosed in the available clinical trial information, so its exact mechanism of action is not described here.
AZD4818 is the primary name used for this investigational drug in clinical trials. No alternative names have been reported in the available clinical trial data, so it is not known to be the same as any other marketed or investigational drug.